Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The STEP-CAT Cohort Management Study: Step-down to Prophylactic Doses of Enoxaparin After a Minimum of 3-6 Months of Anticoagulation for the Treatment of Cancer-associated Thrombosis.

NCT02752607 is registered in ClinicalTrials.gov with Dr. Vicky Tagalakis as lead sponsor.

NCT NCT02752607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02752607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The STEP-CAT Cohort Management Study: Step-down to Prophylactic Doses of Enoxaparin After a Minimum of 3-6 Months of Anticoagulation for the Treatment of Cancer-associated Thrombosis.
Lead sponsor
Dr. Vicky Tagalakis
Phase
Observational
Overall status
Terminated
Start date
May 31, 2016
Completion date
November 9, 2018
Enrollment
52 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

deep vein thrombosis